MAG Antibody Testing
Test in Focus
Mayo Clinic Laboratories now offers an in-house ELISA assay to test for the presence of antibodies against myelin-associated glycoprotein (MAG) antibodies. In this episode of the “Answers From the Lab” podcast, John Mills, Ph.D., discusses how the semi-quantitative, calibrated assay uses unique, human MAG antigen that improves on earlier assays for detection of MAG antibodies. These antibodies are important biomarkers of the rare, hard-to-treat distal acquired demyelinating symmetric neuropathy (DADS).
Although DADS can theoretically be diagnosed through clinical presentation and nerve conduction studies, those finding are less straightforward in practice, says Dr. Mills. “They are complex and heterogenous, and this partly explains why there tends to be a two- to three-year lag in these patients from the time they present with the neuropathy until they formally are diagnosed with DADs or MAG neuropathy.”
Listen to learn more about how incorporating MAG antibody testing into the diagnostic workup can help guide clinicians to the correct diagnosis earlier, equipping them with confidence about disease presence to guide treatment decisions.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluating peripheral neuropathy and paraproteinemic neuropathy.
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.